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Summary 
Toxoflasma gondii tachyzoites markedly alter the profile of eicosanoids  released  by human mononuclear 
phagocytes.  Freshly isolated,  2-h adherent human monocytes release both cyclooxygenase (e.g., 
thromboxane [TX] B2, prostaglandin [PG] E2) and 5-1ipoxygenase (e.g.,  leukotriene [LT] ]]4, 
LTC4) products of arachidonic acid  metabolism after  stimulation by the calcium ionophore 
A23187  or ingestion of opsonized zymosan particles  or heat-killed T. gondii.  However,  after 
incubation with viable T. gondii,  normal and chronic granulomatous disease monocytes release 
only the cyclooxygenase  products TXB2 and PGE2 and fail to form LTB4, LTC4, or other 5-1ipoxy- 
genase products. Monocytes maintained in culture for 5 d lose this capacity  to release TXB2 
and PGE2 after  incubation with  T. gondii.  T. gondii  significantly inhibit calcium ionophore 
A23187-induced LTB4 release by monocyte-derived macrophages; heat-killed organisms do not 
affect this calcium ionophore A23187-induced release of LTB4. T. gondii-induced  inhibition of 
LTB4 release by calcium ionophore A23187-stimulated monocyte-derived macrophages is reversed 
by interferon (IFN)-3'  treatment of the monolayers.  LTB4 induced extensive  damage to the 
cellular membranes and cytoplasmic contents of the organisms as observed by transmission electron 
microscopy. Exogenous LTB4 (10- 6 M) induced intracellular killing of ingested T. gondii by non- 
IFN-q,-treated  monocyte-derived macrophages.  IFN-y-induced  antitoxoplasma  activity  in 
monocyte-derived macrophages was inhibited by the selective 5-1ipoxygenase inhibitor zileuton 
but not by the cyclooxygenase inhibitor indomethacin. These findings suggest a novel role for 
5-1ipoxygenase arachidonic acid products in human macrophage IFN-3,-induced antitoxoplasma 
activity. 
H 
uman monocytes, but not monocyte-derived macro- 
phages, are cytotoxic to Toxoplasma gondii, an obligate 
intracellular protozoal parasite  (1-3).  Monocytes possess a 
granule peroxidase identical to myeloperoxidase (MPO) 1 of 
neutrophils and respond to stimulation with a respiratory 
burst leading to the formation of superoxide anion (Of) and 
hydrogen peroxide (H202) (4). Monocytes derived from pe- 
ripheral blood and maintained as adherent cells in culture un- 
dergo a variety of biochemical and morphologic changes and 
differentiate into cells resembling tissue macrophages (5-7). 
During this transformation in culture, there is a progressive 
loss of the granule peroxidase  (5, 8); after an initial rise at 
day 3, H202 release also greatly decreases (9). Treatment of 
1 Abbreviations used in this paper: CGD, chronic granulomatous  disease; 
HETE, hydroxyeicosatetraenoic  acid; IFA, indirect  fluorescence  antibody; 
LT, leukotriene;  MPO, myeloperoxidase;  TX, thromboxane. 
monocyte-derived macrophages with IFN-3, results in their 
activation with a concomitant increase in H202 generation 
when stimulated (7,  10). 
The capacity to generate oxygen radicals and the presence 
of MPO has been correlated with the antiprotozoal activity 
of phagocytes (2,  11, 12). Neutrophils and freshly isolated 
peroxidase-containing monocytes release large amounts of 
Of and H202 after incubation with T. gondii or other pro- 
tozoa (e.g., Leishmania donovani and Trypanosoma cruzi); these 
phagocytes rapidly destroy the ingested T. gondii (13). In con- 
trast, by day 5 in culture, monocyte-derived macrophages fail 
to kill ingested protozoa, which proceed to replicate intracel- 
lularly (1, 2,  14). The failure of lysosomes to fuse with the 
T. gondii-containing  phagosomes is a striking feature of this 
infection (15, 16). IFN-3, activates monocyte-derived macro- 
phages to significantly increase their respiratory burst activity 
and augment their cytotoxic activity against  such intracel- 
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Chronic granulomatous disease (CGD) monocytes that fail 
to undergo a respiratory burst have a marked impairment in 
toxoplasmacidal and toxoplasmastatic  activities (2). However, 
their toxoplasmastatic activity is augmented by IFN-3' treat- 
ment, suggesting activation of an oxygen-independent an- 
tiprotozoal system in these phagocytes (2). 
As observed in human monocyte-derived macrophages, T. 
gondii inhibit respiratory burst activity and phagolysosomal 
fusion in resident murine peritoneal macrophages (18, 19). 
Furthermore,  T. gondii alter the metabolism of arachidonic 
acid in murine peritoneal macrophages. Resident routine mac- 
rophages release the 5-1ipoxygenase arachidonate products leu- 
kotriene (LT) B4 and LTC4 after incubation with the calcium 
ionophore A23187  and LTC4 and LTD4 after ingestion of 
opsonized zymosan particles (19). In contrast,  T. gondii in- 
hibit 5-1ipoxygenase product release and shift arachidonic acid 
metabolism to monohydroxyeicosatetraenoic acid (HETE) (i.e., 
11-, 12-, and 15-HETE) release by these macrophages.  Viable 
T. gondii are required for this alteration in arachidonic acid 
metabolism since heat-killed T. gondii induce release of LTDa 
but not mono-HETEs from the murine macrophages (19). 
We report here that human mononuclear phagocyte ei- 
cosanoid  metabolism  is  altered  by  T. gondii  tachyzoites. 
Whereas 5-1ipoxygenase arachidonate  products (LTB4, LTC4) 
are released by freshly isolated human peripheral blood mono- 
cytes  incubated with  soluble (i.e.,  the calcium ionophore 
A23187) or particulate (i.e., opsonized zymosan or heat-killed 
T. gondii) stimuli, viable T. gondii fail to induce 5-1ipoxygenase 
product release by these cells. Furthermore, T. gondii inhibit 
LTBa  release  by  calcium  ionophore  A23187-stimulated 
monocyte-derived  macrophages;  this  inhibitory  effect  is 
reversed by IFN-% We also report that LTBa exerts  potent 
cytotoxic activity against T. gondii. The selective 5-1ipoxygenase 
inhibitor zileuton but not the cyclooxygenase inhibitor in- 
domethacin blocks IFN-y-induced antitoxoplasma activity 
in monocyte-derived macrophages. These data suggest that 
inhibition of macrophage LT release may be an important 
mechanism used by T. gondii in their evasion of host inflam- 
matory responses. 
Materials  and Methods 
Special Reagents.  LTB4,  LTC4, LTD4, 5-HETE, 11-HETE, 12- 
HETE,  15-HETE, PGE2, 6-keto-PGFa~, and thromboxane (TX) 
B2 were obtained from Cayman Chemical Co., Inc. (Ann Arbor, 
MI). These eicosanoids were supplied in ethanol with dilutions 
made in PBS. 3H-LTB4, 3H-LTC4, 3H-PGE2, 3H-6-keto-PGFl~, and 
3H-TXB2 were obtained from New  England Nuclear (Boston, 
MA). The cyclooxygenase  inhibitor indomethacin was dissolved 
in ethanol at a concentration of 10 -2 M and diluted with PBS. 
The selective  5-1ipoxygenase  inhibitor zileuton [N-(1-benzolblthien- 
2-ylethyl)-N-hydroxyurea]  (20) was kindly provided by R. L. Bell 
(Abbott Laboratories, Abbott Park, IL). Zileuton was dissolved  in 
DMSO and then diluted in PBS with a final concentration of  0.1% 
DMSO. The final pH of the indomethacin and zileuton solutions 
was 7.0. Recombinant human IFN-3~ was generously provided by 
P. Trown (Hoffmann-La Roche, Nutley, NJ). IFN-'y activity was 
determined by the manufacturer by use of the WISH cell line (CCL 
25; American Type Culture Collection [ATCC], Rockville MD)/ 
vesicular stomatitis virus (VSV) cytopathic effect microtiter assay 
that was standardized  with the National Institutes of Health (NIH) 
human IFN-y reference standard Gg 23-901-530. 
Human Subjects.  Monocytes  were isolated from the blood of 
normal human adult subjects and a patient with CGD. The sub- 
jects had not ingested acetylsalicylic  acid or other nonsteroidal an- 
tiinflammatory drugs for 2 wk before the study; the CGD patient 
was not on IFN-'y prophylaxis. Each subject was negative for T. 
gondii-specific IgM and IgG antibodies by an indirect fluorescence 
antibody (IFA) test (Microbiological Research Corp., Bountiful, 
UT). As previously described (21), the test serum was incubated 
with T. gondii (RH strain) fixed on microscope slides. After reac- 
tion with either fluorescein-conjugated  anti-human IgG (3~ chain 
specific) or ftuorescein-conjugated  IgM (# chain specific), the T. 
gondii were examined  by fluorescence  microscopy  for the character- 
istic peripheral staining  pattern. The absence of  prior acute or chronic 
T. gondii infection was indicated by the lack of fluorescence at a 
1:8 serum IgM-IFA titer and 1:16 serum IgG-IFA titer, respectively. 
Normal sera that had been heat inactivated at 56~  for 45 min 
were used at a 1:10 dilution  (final concentration) in the LTB4- 
Toxoplasma interaction studies. 
Monocytes and Monocyte-derived  Macrophages.  As previously de- 
scribed for monocyte isolation (7), venous blood was collected in 
0.5% K2 EDTA, diluted 1:1 (vol/vol) with Ca  2§  PBS, 
centrifuged at 125 g for 20 min at 4~  and the platelet-containing 
supernatants discarded. After washing in Ca2§  PBS, 
the cell pellets were resuspended in Ca2+/Mg2+-free PBS con- 
taining 0.3  mM Na2EDTA and underlayered with Histopaque 
1077 (Sigma Chemical Co., St. Louis, MO) at a ratio of 1.5:1 (cell 
suspension/Histopaque; vol/vol) before centrifugation at 800 g for 
25  min  at  23~  (22). The  mononuclear cells located in  the 
Ca  2§  PBS:Histopaque  interface were collected, washed 
twice with Ca2+/Mg2+-free PBS, and resuspended in RPMI 1640 
media buffered with 10 mM Hepes (Whittaker M.A. Bioproducts, 
Walkersville, MD) and supplemented with 2 mM r-glutamine, 25 
U/ml penicillin G, and 25 #g/ml streptomycin (GIBCO BILL, 
Gaithersburg, MD). At a concentration of 3  x  106 monocytes  per 
milliliter, the cells were added to sterile 60 x  15 mm tissue culture 
plates (Falcon  3801 Primaria; Becton Dickinson & Co., Mountain 
View, CA)  and  allowed to  adhere for  2  h  at  37~  in  5% 
CO2/95% air with humidity. The plates were washed with sterile 
PBS to remove nonadherent cells. Adherent monocytes were either 
used immediately or  maintained for  5  d  in  culture  to  obtain 
monocyte-derived macrophages, with RPMI  media containing 
10-15% autologous serum changed daily. Some monolayers  were 
stained with Diffquik (Difco Laboratories, Inc., Detroit, MI) for 
evaluation of cell morphology or benzidine dihydrochloride  to de- 
tect peroxidase (23). In some studies, the media  contained 100 U/ml 
recombinant human IFN-y. All buffers and media were prepared 
with sterile nonwrogenic water (Baxter Healthcare  Corp., Deerfield, 
IL) and were filtered  before use with 0.22 #m filter units (Corning 
Inc., Corning, NY). All glassware  had been heated  for 24 h at 170~ 
to destroy endotoxin. 
T. gondii.  The  T. gondii RH  strain was  maintained by in- 
traperitoneal passage in  BALB/c mice (21). After lavage with 
Ca2+/Mg~+-free PBS, the peritoneal fluid was filtered through a 
3-#m polycarbonate filter (Nucleopore Corp., Pleasanton, CA) to 
remove leukocytes. The T. gondii were centrifuged at 1,000 g for 
15  min at 4~  washed twice with Ca2+/Mg2§  PBS, and 
resuspended in PBS before use. The organisms were >95% viable 
as assessed by trypan blue exclusion (24). In selected studies, T. 
gondii were killed by heating at 100~  for 5 rain. 
Eicosanoid Studies.  The monocytes or day 5 monocyte-derived 
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Tyrode's buffer before addition of the reaction components in a final 
volume of 3 ml Tyrode's buffer. The cell monolayers were incubated 
at 37~  in 5% CO2/95%  air with the calcium ionophore A23187 
(Sigma Chemical Co.; 2.5 #M) for 20 min, or opsonized zymosan 
particles (ICN Biomedicals, Inc., Costa Mesa, CA;  1 mg/ml) for 
90  rain,  or  T. gondii  (viable  or  heat  killed)  at  a  ratio  of 1:5 
(mononuclear phagocyte:organism) for 30 min at 37~  In some 
studies,  the monolayers after incubation with T. gondii for 90 min 
were then stimulated with the calcium ionophore A23187 (2.5/xM) 
for 20 min. Zymosan was opsonized by incubation for 15 rain at 
37~  with 50% normal human serum from an individual negative 
for T. gondii-specific  IgG and IgM antibodies (i.e., IgG-IFA titer 
<1:16 and IgM IFA titer <1:8). The zymosan particles were washed 
free  of  unbound  serum  components  before  addition  to  the 
monolayers. At the completion of the incubation periods, the reac- 
tion mixtures were collected, centrifuged at 250 g for 10 min at 
4~  and the supernatants stored at  -70~  until assayed for ei- 
cosanoids by HPLC or RIA. 
The reaction mixture supernatants underwent solid phase ex- 
traction with I ml octadecyl Baker-10 columns (J. T. Baker Chem- 
ical Co., Phillipsburg,  NJ) (25).  The eluants were evaporated to 
dryness under nitrogen, resuspended in methanol, and centrifuged 
at 3000g for 5 rain at 4~  The clear supematant underwent reverse- 
phase HPLC on a 5#zm particle size 2.1  x200 mm Cls microbore 
column (Hypersil ODS; Hewlett-Packard Co., Palo Alto, CA) with 
use of methanol/water/acetic acid (75:25:0.01, vol/vol/vol), pH 4.7, 
at a flow rate of 1 ml/min. A liquid chromatograph with diode 
array detector (models 1090 and 1040; Hewlett-Packard Co.) were 
used to monitor eluting peaks at 235 and 270 nm with rapid UV 
spectral scanning for identification of compounds that cochromato- 
graphed with authentic LT and HETE standards (26).  The mean 
retention  times  for these compounds  are  as follows:  LTB4, 2.4 
rain; LTC4, 3.7 min; 15-HETE, 4.4 min; 11-HETE, 4.7 rain;  12- 
HETE,  4.9  rain;  LTD4,  5.3  rain;  and  5-HETE,  6.0  rain.  The 
limits of detection of lipoxygenase products by reverse-phase HPLC 
are as follows:  LTB4, 25 ng; LTC4, 50 ng; LTD4, 50 ng; 5-HETE, 
30 ng; 11-HETE, 65 rig;  12-HETE, 65 ng; and 15-HETE, 65 ng. 
LTB4, LTC4, PGEz, and the respective stable hydrolysis products 
of PGI2, TXA2, 6-keto-PGFa~, and TXBz were assayed in the reac- 
tion mixture supernatants by RIA. Each RIA was performed in 
duplicate according  to standard protocols.  Unlabeled  and 3H-labeled 
synthetic eicosanoid  standards  were obtained from Cayman Chem- 
ical  Co.  and New England Nuclear,  respectively. 
Rabbit antisera against LTB4 and LTC4 were kindly provided 
by Drs.  Robert W.  Egan and John L.  Humes (Merck Research 
Laboratories, Rahway, NJ) (27). The LTB4 antiserum had a sensi- 
tivity of 10 pg per 0.1-ml sample and the following cross-reactivities 
at B/Bo 50%: 5(S),  12(R)-LTB4, 100%; 5(S),  12(R)-6-trans-LTB4, 
6%; 5(S), 12(S)-6-trans-LTB4, 0%; 5(S),  12(S)-LTB4, 0.2%; 5(S), 
12(S)-6,  10-trans-8,14-cis-di-HETE,  <7.0%; 20-OH-LTB4, 2.0%; 
20-COOH-LTB4,  0%;  5-HETE,  0.2%;  LTC4,  0.02%;  LTD4, 
0.04%; LTE4, 0.15%, LTF4, 0%; and arachidonic acid,  0%. The 
LTC4 antiserum had a sensitivity of 20 pg per 0.1-ml sample and 
the  following  cross-reactivities  at  B/Bo  50%:  (5S,  6R)-LTC4, 
100%; LTD4, 43%; 11-trans-LTD4, 47%; LTE4, 6%; LTF4, 50%; 
(5R,  6R)-LTC4,  100%;  (5S,  6S)-LTC4,  1.7%;  (SR,  5S)-LTC4, 
0.7%;  LTC4-sulfone,  10%;  LTD4-sulfone,  7%;  LTE4-sulfone, 
0.4%;  LTF4-sulfone,  1.0%;  and LTB4, (5S, 6R)-7,8,9,10,11,12, 
14,15-octahydro-LTC4,  PGE2,  PGF2~, glutathione,  5-HETE, and 
arachidonic acid,  each <0.2%. 
The PGE2, 6-keto-PGFl,, and TXB2 antisera were produced in 
rabbits  in  our laboratory  (28,  29)  by the  method  of Jaffe  and 
Behrman (30). The PGE2 antiserum at a dilution of 1:6,000  had 
a sensitivity of 10 pg per 0.1-ml sample and the following cross- 
reactivities  at  B/Bo  50%:  PGE2,  100%;  PGD2,  0.8%;  PGEa, 
9.3%;  6-keto-PGE2, 2.0%;  PGFI~, 0.3%;  6-keto-PGFl~, 2.2%; 
and PGFz~,  1.0%.  The 6-keto-PGF~ antiserum at a dilution  of 
1:6,000  had a sensitivity of 10 pg per 0.1-ml sample and the fol- 
lowing  cross-reactivities  at  B/Bo  50%:  6-keto-PGFl~,  100%; 
PGD2, 0.42%;  PGE1,  0.1%;  PGE2,  0.11%,  6-keto-PGE2, 2.5%, 
PGF2,~, 1.43%; and PGF~, 0.77%. The TXB2 antiserum at a di- 
lution of 1:100,000 had a sensitivity of I pg per 0.1-ml sample and 
the  following  cross-reactivities  at  B/Bo  50%:  TXB2,  100%; 
PGD2,  0.53%;  PGF2,,,  <0.2%;  and  6-keto-PGE2,  PGF~,  and 
6-keto-PGF~, each <0.02%. 
Morphologic Studies.  T. gondii (2  ￿  107) were incubated for 30 
rain at 37~  in PBS in the absence or presence of LTB4 at the con- 
centrations indicated in the legends to Figs. 4 and 5. The prepara- 
tions were then centrifuged at 1,000 g for 15 rain before fixation. 
In studies to assess antitoxoplasma activity of LTB4, human mono- 
cyte--derived  macrophages incubated in the absence of IFN-3' for 
5 d were challenged with T. gondii (1:5 ratio, macrophage:organism) 
for 30 rain at 37~  washed three to five times in  CaZ§  2+- 
free PBS, and incubated in the absence or presence of 10 -6 M LTB4 
in RPMI media containing 10% autologous serum for 60 min at 
37~  The preparations were washed again in  CaZ§ 
PBS and incubated in RPMI media with 10% autologous serum 
for an additional  23  h  at 37~  in  5%  C02/95%  air with hu- 
midity.  The  samples were  fixed  in 4%  glutaraldehyde  and  2% 
paraformaldehyde in 0.1 M  sodium cacodylate buffer, pH 7.4, for 
2 h. The samples were prepared for transmission electron micros- 
copy, with thin sections placed on a 200-mesh grid coated with 
1% Parlodion (Mallinckrodt Inc., St. Louis,  MO) and examined 
on an electron microscope (model 100B; JEOL Ltd., Tokyo, Japan) 
at 60 kV as described previously (31). 
The distribution of morphologic changes induced in the T. gondii 
after incubation  with  LTB4 was  determined  by morphometric 
analysis  as  described  previously  (31, 32).  The  organisms  were 
classified as exhibiting either no cytotoxic changes or one of the 
following cytotoxic characteristics:  (a) intracellular vacuole forma- 
tion; (b) extrusion of cytoplasm into the space between the inner 
and outer surface membrane units; (c) extracellular release of cyto- 
plasmic material; or (d) surface membrane vesiculation and disrup- 
tion. 10 randomly selected  fields in each grid were photographed 
at a magnification of 7,000  for morphometric analysis. 
The role of cyclooxygenase versus  5-1ipoxygenase  arachidonic 
acid products in macrophage antitoxoplasma activity was also as- 
sessed. Monocyte-derived macrophages adherent to 22-mm square 
glass coverslips  were incubated in RPMI media containing  10% 
autologous  serum  and  IFN-3'  (100  U/ml)  for  5  d  in  5% 
COJ95%  air with humidity. After washing, the monolayers were 
incubated with freshly isolated T. gondii (1:5 ratio, macrophage:or- 
ganism) in media alone or media containing either the cycloox- 
ygenase inhibitor  indomethacin  (10 -6 M)  (33)  or  the  5-1ipoxy- 
genase inhibitor zileuton (10 -6 M) (20,  34) for 30 rain at 37~ 
Noningested organisms were then removed by washing,  and the 
cell monolayers were either fixed with 5% formalin (time 0) or 
incubated in RPMI media containing  10%  autologous serum in 
the absence or presence of indomethacin or zileuton for an addi- 
tional 6  h  before fixation in  5%  formalin.  After staining  with 
Giemsa, the number of intracellular T. gondii per macrophage was 
assessed by light microscopy at a magnification of 400 by use of 
a Whipple micrometer disc (Bausch & Lomb Inc., Rochester, NY). 
To confirm that zileuton is a selective inhibitor of the 5-lipoxygenase 
pathway under the conditions of these experiments, IFN-y-treated 
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zileuton for 30 min were stimulated with the calcium ionophore 
A23187 (10 #M) for 20 min at 37~  The supernatants of the reac- 
tion mixtures  were assayed for the 5-1ipoxygenase product  LTB4 
and the cyclooxygenase product TXB2 by RIA as described above. 
Statistical Analysis.  The data are reported  as the mean  _+  SE 
of  the  combined  experiments.  Differences  were  analyzed for 
significance (p <0.05)  by Student's  two-tailed  t test for indepen- 
dent means. 
Results 
Monocytes.  Greater than 95% of freshly isolated (2-h ad- 
herent)  normal human monocytes were peroxidase positive 
and had the characteristic morphology of monocytes by light 
microscopic  evaluation  of  Diffquik-stained  preparations. 
Human  monocytes  incubated  in  buffer  alone  for  90  rain 
released low levels  (<33 pg per  105 monocytes) of each of 
the following eicosanoids:  LTB4 and LTC4 (Figs.  1 A  and 
2) and TXB2, PGE2, and 6-keto-PGFl,~  (Fig. 2); 5-,  11-, 12-, 
and 15-HETE were not detected in these monocyte superna- 
tants. 63% of the total eicosanoids released by these control 
monocytes were cyclooxygenase products (Fig.  3).  T. gondii 
incubated in buffer alone for 90 min release  PGE2 (73.4 pg 
per 106 organisms in 90 min as we have previously reported 
[21]) but do not generate mono-HETEs  or 5-1ipoxygenase 
products. 
When human monocytes were incubated with  T. gondii 
(1:5 ratio,  monocyte:organism),  release of TXB2 and PGE2 
was augmented  15.5-fold  (p <0.02)  and  9-fold  (p <0.05), 
respectively, compared with control (Fig.  2). TXB2 was the 
predominant eicosanoid released by the T. gondii-stimulated 
monocytes (356 pg TXB2 per 105 monocytes, Fig. 2; 56.6% 
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Figure 2.  Effect of T. gondii on eicosanoid release  by human mononuclear 
phagocytes.  Normal monocytes  (MONO) after adherence to plastic for 
2 h and monocyte-derived  macrophages  cultured for 5 d in the absence 
(Day 5 M~) or presence of 100 U/ml recombinant  human IFN-3' (Day 
5 M~b +  IFN-%) were incubated at 37~  for 90 rain in the absence (CON- 
TROL), or presence of viable or heat-killed T. gondii (A TOXO; 1:5 ratio), 
or opsonized  zymosan particles (1 mg/ml), or for 20 min with the cal- 
cium ionophore A23187 (2.5 #M). In some studies, the phagocytes were 
incubated  at 37~  for 90 min with either viable or heat-killed  T. gondii 
followed by incubation  for an additional  20 min with the calcium iono- 
phore A23187 (2.5 #M). Cyclooxygenase (i.e., PGE2, 6-keto-PGFl~,, and 
TXB2) and 5-1ipoxygenase (i.e., LTB4 and LTC4) arachidonate  products 
were assayed by RIA as described in Materials and Methods.  The number 
of studies performed for each condition is shown within the 6-keto-PGF1~ 
graph.  *p <0.05 compared with control (i.e., monocytes, day-5 monocyte- 
derived macrophages,  or IFN-7-treated day-5 monocyte-derived  macro- 
phages  incubated  in buffer  alone).  ~p <0.05  compared  with non-IFN- 
"y-treated day-5 monocyte-derived  macrophages. 
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Figure  1.  Effect of T. goMii on 
human  monocyte eicosanoid re- 
lease. Freshly isolated normal (,4, 
B, and D) and CGD ((7) mono- 
cytes after adherence to plastic for 
2 h were incubated at 37~  in the 
absence (.4) or presence (B and C) 
of T. gondii tachyzoites (1:5 ratio; 
monocyte/organism) for 90 rain 
or with 2.5  #M of the calcium 
ionophore A23187 (D) for 20 rain. 
The  supernatants  underwent 
reverse-phase HPI.C with UV ab- 
sorbance measured at 270 nm as 
described  in  Materials  and 
Methods. 
of total eicosanoids assayed, Fig. 3). T. gondii did not stimu- 
late a significant  release  of LTB4, LTC4 (Figs.  1 B  and 2), 
or 6-keto-PGF~,~ (Fig.  2), or 5-,  11-, 12-, or 15-HETE (not 
shown) above that by monocytes alone. Similarly,  freshly iso- 
lated CGD monocytes failed to release LTB4 or LTC4 (Fig. 
1 C) but did generate TXB2 (mean 399 pg per 10  s cells,  n 
=  2) and PGE2  (mean 227 pg per  105 cells,  n  =  2) after 
incubation with T. gondii. 88.7 (Fig. 3) and 91.8% of eicosa- 
noids released by T. gondii-stimulated  normal and CGD mono- 
cytes, respectively were cyclooxygenase products. 
In  contrast,  heat-killed  T. gondii  significantly  increased 
LTB4 (p <0.05),  TXB2 (p <0.02),  and PGE2 (p <0.05)  re- 
lease above control (Fig.  2).  Approximately equal amounts 
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Figure 3.  Effect  of T. gondii on the profile of cyclooxygenase  and 5-1ipoxy- 
genase arachidonate products released by human mononuclear phagocytes. 
The percentage  of each cyclooxygenase (CO) (i.e., PGE2, 6-keto-PGF1~, 
and TXB2) and 5-1ipoxygenase (5-LO) (i.e., LTB4 and LTC4) product  of 
the total eicosanoids assayed for each experimental condition described in 
Fig.  2 is shown. 
noid released (Figs. 1 D, 2, and 3). Incubation of the mono- 
cytes with either viable or heat-killed  T. gondii before cal- 
cium ionophore A23187 stimulation did not alter significantly 
the amount of LTB4 or other eicosanoids released compared 
with that released  by monocytes incubated with calcium iono- 
phore A23187 alone (Figs. 2 and 3). 
Monocyte-derived Macrophages.  Human peripheral  blood 
monocytes were maintained in culture for 5 d, during which 
period they lose their endogenous peroxidase activity (7, 9). 
T. gondii failed to  stimulate  the  release of TXB2,  PGE2, 
6-keto-PGFl~,  LTB4, LTC4 (Fig. 2), or mono-HETEs (not 
shown) by the day 5-adherent monocyte-derived macrophages 
compared with controls.  Although the total amount of ei- 
cosanoids  released  by  zymosan-  and  calcium  ionophore 
A23187-stimulated monocyte-derived macrophages decreased 
by 2.7- and 12.7-fold, respectively, compared with freshly 
isolated monocytes, these cultured cells remained capable of 
eicosanoid release (Fig. 2). Compared with unstimulated cul- 
tured cells, TXB2 release by the day 5-adherent cells was in- 
creased 4.1-fold (p <0.02) by incubation with zymosan.  As 
with freshly isolated  monocytes,  cyclooxygenase products 
(80.2%  of  eicosanoids  assayed)  were  the  predominant 
arachidonate metabolites released by the zymosan-stimulated 
monocyte-derived  macrophages  (Fig. 3). 
The calcium ionophore A23187 increased day 5 monocyte- 
derived macrophage release of TXB2 by 8.1-fold (p <0.05) 
and LTB4 by 30.6-fold (p <0.001)  compared with controls 
(Fig. 2). LTB4 (61.8% of assayed eicosanoids) was the pre- 
dominant arachidonate product released  by calcium ionophore 
A23187-stimulated  monocyte-derived macrophages (Fig. 3). 
Prior incubation of the monocyte-derived macrophages with 
viable T. gondii before calcium ionophore A23187 stimula- 
tion significantly inhibited the ionophore-induced release of 
5-1ipoxygenase products by these cells. An 8.7-fold reduc- 
tion (p <0.02) in the calcium ionophore A23187-stimulated 
of LTB4 (116 pg per 10  s cells) and TXB2 (126 pg per 105 
cells) were released by monocytes incubated with heat-killed 
T. gondii (Fig.  2).  Opsonized  zymosan induced LTB4 (p 
<0.001),  LTC4 (p <0.05), and TXB2 (p  =  0.0001) release 
above background levels (Fig. 2). As in T. gondii-stimulated 
cells, cyclooxygenase products were the principal eicosanoids 
released by heat-killed  T. gondii- and zymosan-stimulated 
monocytes (67 and 68%, respectively of total eicosanoids as- 
sayed, Fig. 3). 
The soluble stimulus calcium ionophore A23187 induced 
both a marked increase in the total amount and a change in 
profile of eicosanoids released by the human monocytes com- 
pared with that induced by T. gondii or zymosan particles. 
Calcium ionophore A23187-induced eicosanoid release was 
17.0-, 30.4-,  and 16.1-fold greater than that stimulated  by 
freshly isolated T. gondii, heat-killed  T. gondii, and zymosan 
respectively (Fig. 2).  5-Lipoxygenase products  constituted 
89.5%  of the assayed arachidonate metabolites produced by 
calcium  ionophore  A23187-stimulated  cells with  LTB4 
(79.2% of total eicosanoids assayed), the predominant eicosa- 
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Figure  4.  Morphometric analysis of the cytotoxic effect of LTB4 against 
T. gondii. T. gondii tachyzoites were incubated in PBS in the absence (con- 
trol)  or presence  of LTB4 (10 -1~ -  10 -6 M) at 37~  for 30 min.  The 
samples were prepared for transmission electron microscopy, and the per- 
centage distribution  of T. gondii cytotoxic changes was determined by mor- 
phometric analysis as described in Materials and Methods.  1,157 T. gondii 
were randomly  selected and examined for these  studies. 1642  Toxoplasma  gondii Alters Human Mononuclear Phagocyte Eicosanoid Release release of LTBa by these cells was observed (Fig. 2); this level 
of LTB4 was not significantly different from that released by 
day 5 cells alone. In contrast, prior incubation of the monocyte- 
derived macrophages with heat-killed T. gondii did not affect 
the calcium ionophore A23187-induced release of eicosanoids 
by these monolayers (Figs.  2 and 3). 
IFN-T-treated Monocyte-derived Macrophages.  Monocytes 
were maintained in culture for 5 d in the presence of IFN-y 
(100 U/ml).  IFN-y treatment did not significantly alter the 
release of either cyclooxygenase or 5-1ipoxygenase products 
by monocyte-derived macrophages incubated with T. gondii 
(viable or heat killed),  zymosan, or the calcium ionophore 
A23187 alone compared with similarly stimulated cells in- 
cubated in the absence of IFN-y (Fig. 2). However, IFN-y 
restored the ability of T. gondii-infected  monocyte-derived 
macrophages to release LTB4 after stimulation with the cal- 
cium ionophore A23187. Calcium ionophore A23187-stimu- 
lated release of LTB4 by T. gondii-infected monocyte-derived 
macrophages  was augmented  14.5-fold (p <0.02)  in  IFN- 
y-treated cells compared with cells incubated in the absence 
of IFN-y (Fig.  2).  LTB4 constituted  67.3%  of eicosanoids 
released by the IFN-y-supplemented monolayers stimulated 
with calcium ionophore A23187 after prior incubation with 
T. gondii  (Fig.  3). 
Since (a)  T. gondii  fail  to stimulate either LTB4 or LTCa 
release by human mononuclear phagocytes, (b) IFN-y reverses 
T. gondii-induced  suppression of LTBa generation in mono- 
cyte-derived macrophages,  and (c) IFN-y stimulates macro- 
phage toxoplasmacidal activity (1-3), we examined whether 
5-1ipoxygenase arachidonic acid products exert cytotoxic ac- 
tivity against  these organisms.  As determined by morpho- 
metric analysis  of transmission electron micrographs,  LTBa 
(10-1~  M) induced cytotoxic changes in the  T. gondii 
(Fig.  4). 28.1% of the tachyzoites showed evidence of cyto- 
toxic injury after incubation with 10 -6 M LTB4 in PBS for 
30 min compared with 2% of control organisms incubated 
in buffer either  alone (Fig.  4) or containing  0.5%  ethanol 
(vehicle control, not shown). LTB4-induced antitoxoplasma 
activity was not significantly  affected by the presence of serum; 
24.9%  of T. gondii  tachyzoites  (n  =  169)  exhibited cyto- 
toxic changes after incubation for 30 min in PBS containing 
10 -6 M LTB4 and 10% heat-inactivated normal serum that 
was negative for Toxoplasma-specific IgG and IgM antibodies. 
LTB4-mediated  cytotoxic  changes  included  surface  mem- 
brane vesiculation, extravasation of cytoplasmic contents into 
a space between the inner and outer surface membrane units, 
and cytoplasmic vacuolization  in the  T. gondii  (Fig.  5). 
LTB4 also promoted  intracellular  killing  of ingested  T. 
gondii tachyzoites by day 5 monocyte-derived macrophages 
(Fig. 6). Non-IFN-y-treated monocyte-derived macrophages 
after incubation with T. gondii for 30 min were then washed 
to remove noningested organisms  and incubated in the ab- 
sence or presence of LTB4 (10 -6 M) for 60 min  at 37~ 
After washing, the monolayers were maintained in media con- 
taining  10%  autologous serum and examined by transmis- 
sion  electron  microscopy at  24 h.  Whereas  replication  of 
normal-appearing  T. gondii in monocyte-derived macrophages 
was observed 24 h after ingestion of organisms  (Fig.  6 A), 
T. gondii replication was inhibited by incubation of the cells 
after ingestion of organisms with 10 -6 M LTB4 (Fig.  6 B). 
The phagocytic vacuoles in the LTB4-treated cells contained 
damaged T. gondii of irregular shape and altered internal or- 
ganelle structure. Close association of macrophage mitochon- 
dria  with  the  surface  of parasite  vacuoles observed in  T. 
gondii-infected cells (Fig. 6 A) was not present in cells after 
LTBa treatment  (Fig.  6 B). 
The role of cyclooxygenase versus 5-1ipoxygenase products 
in IFN-y-induced macrophage antitoxoplasma activity was 
next examined. IFN-y-treated day-5 monocyte-derived mac- 
rophages were incubated with T. gondii in the absence or pres- 
ence of either the cyclooxygenase inhibitor indomethacin (33) 
or the 5-1ipoxygenase  inhibitor zileuton (20, 34) for 30 min 
at 37~  After washing, the incubations were either termi- 
nated by formalin fixation of the monolayers (0 h) or con- 
tinued in media alone or media containing indomethacin or 
zileuton for an additional 6 h before fixation. IFN-y-treated 
day-5 monocyte-derived macrophages exerted antitoxoplasma 
activity  (Fig.  7).  There  was no  significant  increase in  the 
number of T. gondii present in the IFN-y-treated macrophages 
at 6 h (1.6  _+  0.3 T. gondii per macrophage) compared with 
0 h (1.1  +  0.2 T. gondii per macrophage, p  --  0.3028) (Fig. 
7). IFN-y-induced macrophage antitoxoplasma activity was 
not significantly affected by cyclooxygenase inhibition by in- 
domethacin (10 -6 M). In contrast,  the number of T. gondii 
per macrophage was increased 6.6-fold (6.6  _+  0.8 T. gondii 
per macrophage, p  =  0.0028) at 6 h compared with 0 h (1.0 
+_ 1 T. gonclii per macrophage) in the monolayers treated with 
zileuton.  10 -6 M  zileuton  inhibited  LTB4 release  by 91% 
but did not significantly  affect TXB2 release in IFN-y-treated 
monocyte-derived macrophages stimulated with the calcium 
ionophore  A23187,  confirming  that  zileuton is a selective 
5-1ipoxygenase  pathway inhibitor  in  these studies. 
Discussion 
We report here that  T. gondii tachyzoites markedly alter 
eicosanoid metabolism in human mononuclear phagocytes. 
In particular, 5-1ipoxygenase  arachidonic acid product release 
Figure 5.  Ultrastructure of LTB4-induced T. gondii  cytotoxicity. (A) T. gondii tachyzoites were incubated at 37~  for 30 min in PBS. The nucleus 
(N), mitochondfia (M), rhoptries (R), and other intracellular structures of the crescent-shaped control T. gondii are of normal appearance. The surface 
structure of the organisms consists of intact outer (arrows)  and inner (arrowheads)  membrane units. Bar, 1 #m. (B and C) The T. gondii  were incubated 
at 37~  for 30 min in PBS with LTB4 (10 -6 M). (B) LTB4 induced surface membrane vesiculation (arrowheads).  Extravasation (arrows)  of cytoplasmic 
contents through the inner parasite membrane caused bulging of the outer parasite membrane. Intracellular vacuolation (V) is observed. Bar, 2/zm. 
(C) Swelling of the membrane (arrowheads)  surrounding the nucleus (N) and cytoplasmic  leakage into the space (arrows)  between the inner and outer 
surface membrane units are seen in T. gondii after incubation with LTB4. Swelling of a mitochondrion (M) is also observed. Bar, 1 /zm. 
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ygenase and 5-1ipoxygenase  inhi- 
bition on IFN-'y-mediated  tox- 
oplasmacidal  activity.  Monocyte- 
derived macrophages (M~b) cul- 
tured for 5 d in the presence of 
IFN-qr (100 U/ml) were  incubated 
with T. gondii  (TOXO; 1:5 ratio, 
macrophage/organism)  in media 
alone or with 10- 6  M indometh- 
acin (INDO) or 10 -6 M zileuton 
for 30 rain  at 37~  After  washing, 
the cell monolayers  were either 
fixed  immediately  in 5% formalin 
(0 h) or incubated  in the absence or presence of either indomethacin  or 
zileuton for an additional 6 h before formalin  fixation. The number of 
intracellular T. gondii  per macrophage  was determined  by light microscopic 
examination  of Giemsa-stained  preparations. The data  represent the mean 
+ SE of three experiments.  Probability  values  for the difference  from  mac- 
rophage  +  T. gondii alone are shown where significant  (p <0.05). 
by these cells is suppressed by viable T. gondii. We found that 
LTB4 exerts  cytotoxic activity against  T. gondii  tachyzoites 
promoting intraceUular  killing of these organisms in mono- 
cyte-derived macrophages.  Furthermore,  the inhibition of 
IFN-'?-induced macrophage antitoxoplasma activity by selec- 
tive inhibition of 5-1ipoxygenase suggests an important role 
for 5-1ipoxygenase products in the cytotoxic activity of these 
mononuclear phagocytes against  T. gondii. 
Our data indicate that, in metabolism of arachidonic acid 
by human monocytes, the profile of products released is de- 
pendent on the nature of the specific stimulus. Both cycloox- 
ygenase (i.e., TXB/, PGEz) and 5-1ipoxygenase (i.e., LTB4, 
LTC4) products of arachidonic acid metabolism are released 
by normal human monocytes when stimulated by either par- 
ticulate (i.e., opsonized zymosan particles, heat-killed T. gondii) 
or soluble (i.e.,  calcium ionophore A23187)  stimuli. How- 
ever, the monocytes (in comparison to nonstimulated con- 
trol cells) fail to release significant amounts of 5-1ipoxygenase 
products after ingestion of viable T gondii. Possible explana- 
tions for this finding include the following: (a) LTs formed 
by T. gondii-stimulated normal human monocytes are degraded 
by MPO-H2Oz-halide system oxidants or hydroxyl radicals 
(OH.) released by the phagocytes (25);  and (b)  T. gondii do 
not activate the 5-1ipoxygenase pathway of arachidonic acid 
metabolism. Our findings suggest the second mechanism. 
CGD monocytes, which are unable to respond to stimula- 
tion with a respiratory burst and thus cannot oxidatively de- 
grade LTs, also failed to release 5-1ipoxygenase products after 
incubation with T. gondii. As in normal monocytes, only cy- 
clooxygenase pathway activation occurs in T. gondii-stimu- 
lated CGD  monocytes. 
Cyclooxygenase  arachidonate products were the predomi- 
nant eicosanoids  released by monocytes ingesting viable  T. 
gondii or opsonized zymosan (88.7  and 68.0%  of total ei- 
cosanoids,  respectively).  TXB2 was the predominant eicosa- 
noid released by zymosan-stimulated human monocytes, in 
agreement with previous studies (35).  Similarly,  we found 
that the monocytes after interaction with T. gondii primarily 
release TXB2.  We recently reported that human platelets are 
cytotoxic to T. gondii tachyzoites, and TX release is impor- 
tant in this platelet-mediated toxoplasmacidal activity (21). 
Surface membrane vesiculation and cytoplasmic lysis in the 
T. gondii  are prominent ultrastructural features of TXA2- 
induced injury (21). It is possible that TX generation by freshly 
isolated monocytes may contribute to the previously demon- 
strated (2)  cytotoxic effect of these cells against  T. gondii. 
In  monocytes, the  soluble stimulus calcium  ionophore 
A23187  primarily  induced  the  release  of  5-1ipoxygenase 
arachidonate products (89.5% of total eicosanoids  assayed), 
in agreement with previous studies  (35-38).  LTB4 was the 
major  product  of calcium  ionophore  A23187-stimulated 
monocytes,  with  a  ratio  of TXBjPGE2/LTB4/LTC4  of 
6:1:54:7  observed.  The  calcium  ionophore  A23187  also 
markedly increased  (i.e., up to 30.4-fold) the total amount 
of eicosanoids released by the monocytes compared with that 
induced by the particulate stimuli. Prior incubation of the 
cells with viable T gondii did not significantly alter this pat- 
tern, with a ratio of TXB2/PGEjLTB4/LTC4 of 7:1:43:6 
observed.  These data indicate that T. gondii do not inhibit 
activation of the 5-1ipoxygenase  pathway by a second stimulus 
in fleshly isolated monocytes. 
Trippet al. (39) have reported that when murine perito- 
neal macrophages are maintained in tissue culture, there is 
a progressive decrease in the capacity of these cells to metabolize 
arachidonic acid. By 4 d in culture, they noted a minimum 
release  of both cyclooxygenase (i.e.,  6-keto-PGEl~,  PGE2, 
TXB2)  and  5-1ipoxygenase  (i.e.,  LTC4) products by these 
macrophages. Similarly,  we observed that as human mono- 
cytes differentiate in culture to monocyte-derived macrophages, 
there is a marked reduction in the ability of these cells to 
release eicosanoids after incubation with either soluble or par- 
ticulate stimuli. In general, 5-1ipoxygenase product release 
was inhibited to a greater extent than cyclooxygenase product 
Figure  6.  Effect  of LTB4 on intracellular  killing  of T gondii  by human  monocyte-derived  macrophages. Non-IFN-y-treated  day-5 monocyte-derived 
macrophages were incubated  with T. gondii (1:5 ratio, monocyte-derived  macrophage/organism)  for 30 min at 37~  washed to remove  noningested 
organisms, and then incubated  in the absence (A) or presence (B) of 10 -6 M LTB4 and 10% autologous  serum that was negative  for Toxoplasma-specific 
IgG and IgM antibodies  for 60 min at 37~  After  washing  in Ca  2+/Mg2+-free PBS, the cells were incubated  for an additional  23 h in RPMI media 
containing 10% autologous  serum before fixation  and examination  by transmission  electron microscopy. (A) In this representative T. gondii-infected 
monocyte-derived  macrophage  that was not treated  with LTB4, the nucleus  (N) is of normal appearance and vacuoles  (V) containing  ingested T. gondii 
(T) are seen. Replication  of organisms  within a vacuole  is observed. The crescent-shaped  organisms  contain  a centrally  located  nucleus  (n). Mitochondria 
(34) of the macrophage  are located  close to the surface  (arrows)  of the parasite vacuole. Bar, 1/xm. (B) After  incubation  with LTB4, T. gondii-infected 
monocyte-derived  macrophages  contain  phagocytic  vacuoles  (V) surrounding  disrupted  organisms. T. gondii  (T) of irregular shape (arrowheads)  and loss 
of normal internal organelle structure are seen. Close association  of macrophage mitochondria  (M) with the surface of the parasite vacuoles is not 
observed in these preparations after  LTB4 treatment.  Bar, 1 /xm. 
1645  Yong et al. release in the monocyte-derived macrophages. Monolayers 
maintained in culture for 5 d produced 12.7-fold less total 
eicosanoids after calcium ionophore A23187 stimulation than 
comparably activated  freshly isolated monocytes. LTB4 and 
LTC4 release was decreased 16.3- and 44.4-fold,  respectively 
(17.6-fold  decrease  in  5-1ipoxygenase  products),  whereas 
TXB2  and PGE2 release were decreased 4.1-  and 2.8-fold, 
respectively (3.8-fold decrease in cyclooxygenase products) in 
the calcium ionophore A23187-stimulated day 5 monolayers. 
Release of LTB4 and TXB2 by calcium ionophore A23187- 
stimulated day 5 monolayer cells was still significantly greater 
than that of unstimulated controls, however. In zymosan- 
stimulated monocyte-derived  macrophages, a 2.7-fold decrease 
in total eicosanoids (4.4-fold decrease in 5-1ipoxygenase  prod- 
ucts and 2.3-fold decrease in cyclooxygenase  products) released 
compared with zymosan-activated monocytes was observed. 
In day 5 monolayers incubated with T. gondii, eicosanoid 
release was decreased to a greater extent than in cells incubated 
with zymosan particles. Although freshly isolated monocytes 
release both TXB2 and PGE2 after  ingestion of T. gondii, 
monocytes maintained in culture for 5 d are not stimulated 
by T. gondii to release these cyclooxygenase products. Com- 
pared with freshly isolated monocytes, total eicosanoid re- 
lease fell ninefold in monocyte-derived macrophages incubated 
with T. gondii, with a 15.5- and 9.5-fold reduction in release 
of TXB2 and PGE2, respectively. Furthermore, infection of 
the day-5 monocyte-derived macrophages by T.gondii  prevented 
5-1ipoxygenase pathway activation by a second stimulus, the 
calcium  ionophore A23187.  Failure  of  T. gondii-infected 
monocyte-derived macrophages to release eicosanoids (e.g., 
TXB2 and LTB4) that exert toxoplasmacidal activity may be 
important in the inability of human monocyte-derived mac- 
rophages to kill these parasites. 
We have previously demonstrated that T. gondii cell mem- 
branes  are disrupted by the cyclooxygenase product TXA2 
(generated by platelet microsomal fractions)  (21) and by the 
linoleic acid metabolite 13-hydroxyoctadecadienoic  acid (31) 
but not by the 12-1ipoxygenase product 12-HETE released 
by T. gondii-stimulated  human platelets  (26). As shown in 
this report,  the 5-1ipoxygenase arachidonate product LTB4 
also exerts potent cytotoxic activity against T. gondii tachy- 
zoites. LTB4 induced surface membrane vesiculation, leakage 
of cytoplasmic contents into the space between the inner and 
outer surface membrane units, and intracytoplasmic vacuola- 
tion in T. gondii. Comparable cytotoxic changes occur in T. 
gondii after  incubation with  10 -6 M  LTC4 for 30 rain at 
37~  (Chi, E. Y., and Henderson, W. R., Jr., unpublished 
observations).  We  have  also  found that  incubation of T. 
gondii-infected non-IFN-3,-treated monocyte-derived  macro- 
phages with LTB4 (10 -6 M) for 30 rain results  in intracel- 
lular killing of the pathogens in contrast to intracellular repli- 
cation  of  the  T.  gondii and  disruption  of  the  infected 
macrophages incubated in the absence of LTB4. LTB4 is a po- 
tent chemoattractant for human neutrophils and monocytes 
in vitro and in vivo (40,  41). T. gondii-induced  inhibition 
of mononuclear phagocyte LTB4 release could be an impor- 
tant antiinflammatory mechanism used by the parasites to 
diminish the influx of leukocytes into the tissue sites of T, 
gondii infection. 
We also examined the effect of IFN-3,  activation of the 
human mononuclear phagocytes on the metabolism of ara- 
chidonic acid by these cells. Prior studies have shown that 
activation of murine peritoneal macrophages results in an al- 
teration in both the release of arachidonic acid and profile 
of generated eicosanoids that is dependent on whether the 
cells are activated in vivo or in vitro and the specific stimulus 
triggering eicosanoid release. 
In vivo activation of murine peritoneal macrophages by 
intraperitoneal injection of Corynebacteriurn parvum greatly 
reduces release of PGI2 (42-44),  PGE2 (43, 44), HETEs (44), 
and LTC4 (44) after incubation of cells with zymosan (43, 
44), phorbol myristate acetate (43), or PGH2 (42). However, 
conservation of TXA2 synthesis occurs in murine peritoneal 
macrophages activated in vivo only by treatment with either 
C. parvum (44) or Listeria monocytogenes (45). For example, 
TXA2 synthesis in L. monocytogenes-activated macrophages 
after zymosan stimulation is not significantly different from 
resident peritoneal macrophages, whereas total release of ei- 
cosanoids by the elicited cells is decreased by 94% compared 
with resident macrophages after incubation with zymosan 
(45). In contrast, in vitro activation of murine peritoneal mac- 
rophages by IFN-3/results in diminished release of throm- 
boxane (46) as well as PGI2 (46), PGE2 (46), LTB4 (47), and 
LTC4 (47) after  zymosan stimulation compared with resi- 
dent cells without IFN-y treatment. Tripp et al. (45) have 
proposed that there is a different response to IFN-'y ofmono- 
cytes migrating to the site ofL. monocytogenes  infection com- 
pared with that of resident macrophages, which accounts for 
TXA2 synthesis to be conserved in the in vivo-activated 
mononuclear phagocyte cell populations but downregulated 
in the in vitro IFN-'y-treated cells. 
The nature of the stimulus triggering eicosanoid synthesis 
also affects the profile of cyclooxygenase and 5-1ipoxygenase 
products released by activated  macrophages in comparison 
to resident cells. As described above, IFN-y treatment of mu- 
fine peritoneal macrophages inhibits zymosan-induced  release 
of both arachidonic acid (46)  and all cyclooxygenase (i.e., 
PGE2, TXB2,  PGI2) and 5-lipoxygenase  (i.e., LTB4, LTC4) 
arachidonate products. However, while arachidonic acid and 
LTC4 release is  decreased  in calcium ionophore A23187- 
stimulated IFN-y-activated murine peritoneal macrophages, 
TXA2 release is unaffected,  and PGE2 and PGI2 release is 
augmented compared with resident cells (46). Furthermore, 
total arachidonic acid release is increased in these IFN-3~-treated 
cells after PMA stimulation, which also increases the release 
of PGE2 and PGI2 (46). 
Conflicting reports on the effects of IFN-3/ on human 
monocyte eicosanoid release have been published. In one study 
(48), IFN-3  ~ (500 U/ml)-treatment of monocytes produced 
decreased release of PGE2,  TXB2,  PGF2~, and LTC4 after 
concanavalin A stimulation. However, in monocytes treated 
with IFN-y at a concentration of 10 U/ml and then stimu- 
lated with LPS, different effects on eicosanoid release have 
been observed. Nichols and Garrison (49) reported that such 
1646  Toxoplasma  gondii Alters Human Mononuclear Phagocyte  Eicosanoid Release treatment increases PGE2 release without affecting TXB2 re- 
lease by these cells. In contrast, Browning and Kibolini (50) 
found that PGE2 release was decreased and TXB2 release was 
increased  in monocytes pretreated with IFN-'y before LPS 
stimulation. 
We found that incubation of human monocytes with IFN-3' 
(100 U/ml) for 5 d in culture did not significantly affect the 
release of either cyclooxygenase or 5-1ipoxygenase products 
by the monocyte-derived macrophages after incubation with 
one of the following stimuli: zymosan, the calcium iono- 
phore A23187,  or heat-killed T. gondii. However, IFN-3' re- 
stored the ability of T. gondii-infected  monocyte-derived mac- 
rophages to release LTB4 after calcium ionophore A23187 
stimulation. The inhibition of IFN-'y-mediated toxoplasma- 
cidal activity  by the selective 5-1ipoxygenase inhibitor zileuton 
suggests that 5-1ipoxygenase arachidonic acid metabolites play 
an important role in the mediation of this cytotoxic activity. 
In summary, these data indicate that T. gondii tachyzoites 
fail to activate the 5-1ipoxygenase pathway in human mono- 
cytes and suppress  activation of this pathway in monocyte- 
derived macrophages. This inhibition of mononuclear phago- 
cyte 5-1ipoxygenase product release may be important for the 
survival  of these pathogens in vivo. 
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